Jane Street
ABUS icon

Jane Street’s Arbutus Biopharma ABUS Stock Holding History

Jane Street’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$115K Sell
25,500
-25,600
-50% -$112K ﹤0.01% 10563
2025
Q4 		$246K Buy
+51,100
New +$230K ﹤0.01% 9276
2025
Q2 		– Sell
-17,800
Closed -$62.1K – 9492
2025
Q1 		$62.1K Buy
+17,800
New +$59.4K ﹤0.01% 8951
2022
Q3 		– Sell
-38,000
Closed -$103K – 9601
2022
Q2 		$103K Sell
38,000
-187,700
-83% -$480K ﹤0.01% 8617
2022
Q1 		$673K Sell
225,700
-39,000
-15% -$119K ﹤0.01% 6925
2021
Q4 		$1.03M Buy
264,700
+78,400
+42% +$305K ﹤0.01% 5841
2021
Q3 		$799K Buy
186,300
+143,900
+339% +$480K ﹤0.01% 6363
2021
Q2 		$128K Sell
42,400
-4,500
-10% -$13.9K ﹤0.01% 9146
2021
Q1 		$156K Sell
46,900
-34,800
-43% -$134K ﹤0.01% 8440
2020
Q4 		$290K Buy
+81,700
New +$286K ﹤0.01% 6465

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Jane Street's ABUS Position: Q1 2026 in Review

Jane Street sold out of Arbutus Biopharma (ABUS) in Q1 2026, closing a stake of 83,933 shares — an estimated $367K sold.

Jane Street first reported a position in ABUS in Q1 2014 and held it in 27 quarters. The position peaked at $1.37M in Q4 2021. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • Jane Street reported no remaining Arbutus Biopharma position as of Q1 2026 after selling out during the quarter.
  • Jane Street sold 83,933 Arbutus Biopharma shares in Q1 2026, an estimated $367K.
  • Jane Street first reported a position in Arbutus Biopharma in Q1 2014 and held it in 27 quarters.
  • Jane Street's Arbutus Biopharma position peaked at $1.37M in Q4 2021.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.